Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy

Cancer Science

Volumn 108, Issue 10, 2017, Pages 1947-1952

  Kitamura, Hidemitsu ^a   Ohno, Yosuke ^a,b   Toyoshima, Yujiro ^a,b   Ohtake, Junya ^a   Homma, Shigenori ^b   Kawamura, Hideki ^b   Takahashi, Norihiko ^b   Taketomi, Akinobu ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; dendritic cell; immunosuppression; interleukin 6; STAT 3

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE; CD11B ANTIGEN; CD14 ANTIGEN; CYCLOOXYGENASE 2; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 6; PROTEINASE; STAT3 PROTEIN; IL6 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CELL MATURATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; EFFECTOR CELL; ENZYME ACTIVITY; FUTUROLOGY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL; TARGET CELL DESTRUCTION; TH1 CELL; TRANSCRIPTION INITIATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2; DENDRITIC CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-6; NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT;

EID: 85030173484     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13332     Document Type: Review

References (70)

1. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–7.
2. Coulie PG, Van den Eynde BJ, van der Bruggen P et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135–46.
3. Kumai T, Kobayashi H, Harabuchi Y et al. Peptide vaccines in cancer-old concept revisited. Curr Opin Immunol 2016; 8(45): 1–7.
4. Yang JC, Rosenberg SA. Adoptive T-cell therapy for cancer. Adv Immunol 2016; 130: 279–94.
5. Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol 2016; 28: 401–9.
6. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res 2017; 27: 109–18.
7. Bronte V, Brandau S, Chen SH et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016; 7: 12150.
8. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.
9. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122–33.
10. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–65.
11. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265–77.
12. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39: 38–48.
13. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419–26.
14. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004; 305: 197–200.
15. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548–56.
16. Hirano T, Yasukawa K, Harada H et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73–6.
17. Park SJ, Nakagawa T, Kitamura H et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173: 3844–54.
18. Kitamura H, Kamon H, Sawa SI et al. IL-6-STAT3 Controls intracellular MHC class II αβ dimer level through cathepsin S activity in dendritic cells. Immunity 2005; 23: 491–502.
19. Sumida K, Wakita D, Narita Y et al. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol 2012; 42: 2060–72.
20. Narita Y, Kitamura H, Wakita D et al. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J Immunol 2013; 190: 812–20.
21. Fisher DT, Chen Q, Skitzkiet JJ et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest 2011; 121: 3846–59.
22. Xue T, Liu P, Zhou Y et al. Interleukin-6 induced “Acute” phenotypic microenvironment promotes Th1 anti-tumor immunity in Cryo-Thermal therapy revealed by shotgun and parallel reaction monitoring proteomics. Theranostics 2016; 6: 773–94.
23. Ohno Y, Kitamura H, Takahashi N et al. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells. Cancer Immunol Immunother 2016; 65: 193–204.
24. Knpfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients—a summary of published results. Int J Colorectal Dis 2010; 25: 135–40.
25. Mitsunaga S, Ikeda M, Shimizu S et al. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 2013; 108: 2063–9.
26. Makuuchi Y, Honda K, Osaka Y et al. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci 2013; 104: 1045–51.
27. Gupta N, Goswami B, Mittal P. Effect of standard anthracycline based neoadjuvant chemotherapy on circulating levels of serum IL-6 in patients of locally advanced carcinoma breast - a prospective study. Int J Surg 2012; 10: 638–40.
28. Yoshitomi M, Yutani S, Matsueda S et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012; 3: 463–9.
29. Hazama S, Takenouchi H, Tsunedomi R et al. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Res 2014; 34: 4201–5.
30. Obermajer N, Muthuswamy R, Lesnock J et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118: 5498–505.
31. Lin Y, Gustafson MP, Bulur PA et al. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood 2011; 117: 872–81.
32. Huang A, Zhang B, Wang B et al. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother 2013; 62: 1439–51.
33. Mao Y, Poschke I, Wennerberg E et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013; 73: 3877–87.
34. Sumida K, Ohno Y, Ohtake J et al. IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signaling pathway. Sci Rep 2015; 5: 13650.
35. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190: 617–27.
36. Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698–703.
37. Ohkuri T, Wakita D, Chamoto K et al. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. Br J Cancer 2009; 100: 1135–43.
38. Takahashi N, Ohkuri T, Homma S et al. First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 2012; 103: 150–3.
39. Ohtake J, Ohkuri T, Togashi Y et al. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Immunol Lett 2014; 161: 20–30.
40. Tsukamoto H, Nishikata R, Senju S et al. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol Res 2013; 1: 64–76.
41. Tsukamoto H, Senju S, Matsumura K et al. IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age. Nat Commun 2015; 6: 6702.
42. Tsukamoto H, Fujieda K, Hirayama M et al. Soluble IL-6R expressed by myeloid cells reduces tumor-specific Th1 differentiation and drives tumor progression. Cancer Res 2017; 77: 2279–91.
43. Hsich CS, Macatonia SE, Tripp CS et al. Development of TH1 CD4+ T cells through IL-12 produced by listeria-induced macrophage. Science 1993; 260: 547–9.
44. Morinobu A, Gadina M, Strober W et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci USA 2002; 99: 12281–6.
45. Hoentjen F, Sartor RB, Ozaki M et al. STAT3 regulates NF-kB recruitment to the IL-12p40 promoter in dendritic cells. Blood 2005; 105: 689–96.
46. Kortylewski M, Xin H, Kujawski M et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15: 114–23.
47. Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461–5.
48. Lee SO, Yang X, Duan S et al. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer. Oncotarget 2016; 7: 6626–38.
49. Tu DG, Lin WT, Yu CC et al. Chemotherapeutic effects of luteolin on radio-sensitivity enhancement and interleukin-6/signal transducer and activator of transcription 3 signaling repression of oral cancer stem cells. J Formos Med Assoc 2016; 115: 1032–8.
50. Albino D, Civenni G, Rossi S et al. The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment. Oncotarget 2016; 22: 76756–68.
51. Heo TH, Wahler J, Suh N. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget 2016; 7: 15460–73.
52. Puchalski T, Prabhakar U, Jiao Q et al. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010; 16: 1652–61.
53. Rossi JF, Négrier S, James ND et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010; 103: 1154–62.
54. Karkera J, Steiner H, Li W et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 2011; 71: 1455–65.
55. Fizazi K, De Bono JS, Flechon A et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012; 48: 85–93.
56. Angevin E, Tabernero J, Elez E et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2014; 20: 2192–204.
57. Voorhees PM, Manges RF, Sonneveld P et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013; 161: 357–66.
58. Thomas SK, Suvorov A, Noens L et al. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol 2014; 73: 35–42.
59. Orlowski RZ, Gercheva L, Williams C et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 2015; 90: 42–9.
60. Dijkgraaf EM, Santegoets SJ, Reyners AK et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. Ann Oncol 2015; 26: 2141–9.
61. Lee WS, Kang M, Baek JH et al. Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol 2013; 20: 697–702.
62. Ling A, Edin S, Wikberg ML et al. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer 2014; 110: 2551–9.
63. Turksma AW, Coupé VM, Shamier MC et al. Extent and location of tumor-infiltrating lymphocytes in microsatellite-stable colon cancer predict outcome to adjuvant active specific immunotherapy. Clin Cancer Res 2016; 22: 346–56.
64. Yoshida N, Kinugasa T, Miyoshi H et al. A High RORγT/CD3 Ratio is a strong prognostic factor for postoperative survival in advanced colorectal cancer: analysis of helper T cell lymphocytes (Th1, Th2, Th17 and Regulatory T Cells). Ann Surg Oncol 2016; 23: 919–27.
65. Bellucci R, Martin A, Bommarito D et al. Interferon-g-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 2015; 4: e1008824.
66. Kharma B, Baba T, Matsumura N et al. STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res 2014; 74: 6519–30.
67. Abiko K, Matsumura N, Hamanishi J et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015; 112: 1501–9.
68. Azuma M, Takeda Y, Nakajima H et al. Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology 2016; 5: e1188244.
69. Takeda Y, Kataoka K, Yamagishi J et al. A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy. Cell Rep 2017; 19: 1874–87.
70. Hu Y, Cong X, Chen L et al. Synergy of TLR3 and 7 ligands significantly enhances function of DCs to present inactivated PRRSV antigen through TRIF/MyD88-NF-κB signaling pathway. Sci Rep 2016; 6: 23977.